Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 111 | 2025 | 21056 | 2.180 |
Why?
|
Antineoplastic Agents, Hormonal | 19 | 2022 | 1534 | 1.480 |
Why?
|
Aromatase Inhibitors | 10 | 2025 | 518 | 1.080 |
Why?
|
Neoplasms, Hormone-Dependent | 7 | 2014 | 409 | 0.990 |
Why?
|
Tamoxifen | 10 | 2019 | 963 | 0.740 |
Why?
|
Receptor, erbB-2 | 20 | 2023 | 2593 | 0.650 |
Why?
|
Estradiol | 10 | 2025 | 1947 | 0.600 |
Why?
|
Mastectomy | 16 | 2024 | 1847 | 0.510 |
Why?
|
Selective Estrogen Receptor Modulators | 2 | 2006 | 134 | 0.470 |
Why?
|
Estrogen Antagonists | 6 | 2005 | 150 | 0.460 |
Why?
|
Receptors, Progesterone | 8 | 2021 | 1153 | 0.430 |
Why?
|
Estrogen Receptor Modulators | 2 | 2011 | 58 | 0.420 |
Why?
|
Receptors, Estrogen | 14 | 2021 | 2242 | 0.410 |
Why?
|
Carcinoma, Lobular | 2 | 2008 | 471 | 0.410 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 36 | 2020 | 11868 | 0.370 |
Why?
|
Anxiety | 9 | 2022 | 4671 | 0.330 |
Why?
|
Androstadienes | 3 | 2008 | 347 | 0.330 |
Why?
|
Nitriles | 5 | 2008 | 982 | 0.320 |
Why?
|
Mastectomy, Segmental | 11 | 2022 | 964 | 0.320 |
Why?
|
Triazoles | 5 | 2008 | 897 | 0.320 |
Why?
|
Sexual Partners | 3 | 2022 | 804 | 0.290 |
Why?
|
Pregnancy Complications, Neoplastic | 2 | 2020 | 258 | 0.290 |
Why?
|
Neoplasms, Second Primary | 4 | 2024 | 1050 | 0.280 |
Why?
|
BRCA2 Protein | 4 | 2022 | 800 | 0.280 |
Why?
|
Antineoplastic Agents | 18 | 2021 | 13648 | 0.280 |
Why?
|
Neoplasm Staging | 30 | 2022 | 11206 | 0.260 |
Why?
|
Female | 129 | 2025 | 396112 | 0.260 |
Why?
|
BRCA1 Protein | 4 | 2022 | 1153 | 0.250 |
Why?
|
Prospective Studies | 35 | 2024 | 54802 | 0.240 |
Why?
|
Chemotherapy, Adjuvant | 13 | 2022 | 3537 | 0.220 |
Why?
|
Estrogen Receptor alpha | 2 | 2021 | 578 | 0.220 |
Why?
|
Adult | 92 | 2024 | 223044 | 0.220 |
Why?
|
Breast Feeding | 2 | 2024 | 1364 | 0.220 |
Why?
|
Quality of Life | 10 | 2024 | 13462 | 0.210 |
Why?
|
Quinazolines | 6 | 2013 | 1364 | 0.210 |
Why?
|
Fluorouracil | 12 | 2014 | 1648 | 0.210 |
Why?
|
Fertility | 3 | 2022 | 768 | 0.200 |
Why?
|
Postmenopause | 7 | 2025 | 2515 | 0.190 |
Why?
|
Carcinoma | 3 | 2021 | 2312 | 0.190 |
Why?
|
Humans | 142 | 2025 | 765968 | 0.180 |
Why?
|
Neoplasm Proteins | 1 | 2013 | 3596 | 0.180 |
Why?
|
Gonadal Steroid Hormones | 1 | 2025 | 705 | 0.180 |
Why?
|
Cyclophosphamide | 15 | 2013 | 2228 | 0.180 |
Why?
|
Adaptation, Psychological | 2 | 2022 | 2660 | 0.180 |
Why?
|
Gene Expression | 1 | 2013 | 7584 | 0.170 |
Why?
|
Neoadjuvant Therapy | 3 | 2020 | 2895 | 0.170 |
Why?
|
Decision Making | 5 | 2019 | 3965 | 0.170 |
Why?
|
Neoplasm Recurrence, Local | 16 | 2022 | 9373 | 0.170 |
Why?
|
Young Adult | 25 | 2024 | 59889 | 0.160 |
Why?
|
Gene Expression Profiling | 4 | 2019 | 9525 | 0.160 |
Why?
|
Doxorubicin | 14 | 2013 | 2230 | 0.150 |
Why?
|
Cross-Over Studies | 1 | 2025 | 2108 | 0.150 |
Why?
|
Social Support | 5 | 2022 | 2192 | 0.140 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2023 | 532 | 0.140 |
Why?
|
Combined Modality Therapy | 28 | 2022 | 8529 | 0.140 |
Why?
|
Sexual Dysfunctions, Psychological | 1 | 2019 | 193 | 0.140 |
Why?
|
Carcinoma in Situ | 1 | 2022 | 779 | 0.130 |
Why?
|
Body Image | 3 | 2020 | 644 | 0.130 |
Why?
|
Breast | 3 | 2022 | 1946 | 0.130 |
Why?
|
Attitude | 1 | 2020 | 770 | 0.130 |
Why?
|
Parenting | 1 | 2022 | 709 | 0.130 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2019 | 363 | 0.120 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2022 | 920 | 0.120 |
Why?
|
Patient Participation | 2 | 2015 | 1455 | 0.120 |
Why?
|
Neoplasm Metastasis | 13 | 2018 | 4893 | 0.110 |
Why?
|
Reproductive History | 1 | 2015 | 210 | 0.110 |
Why?
|
Biopsy | 5 | 2022 | 6763 | 0.110 |
Why?
|
Hematopoiesis | 1 | 2022 | 2058 | 0.110 |
Why?
|
Middle Aged | 59 | 2025 | 223009 | 0.110 |
Why?
|
Clinical Trials as Topic | 7 | 2014 | 8041 | 0.110 |
Why?
|
Mammary Glands, Human | 1 | 2014 | 199 | 0.110 |
Why?
|
Employment | 1 | 2019 | 1106 | 0.100 |
Why?
|
Amenorrhea | 2 | 2014 | 470 | 0.100 |
Why?
|
Radiotherapy | 3 | 2017 | 1494 | 0.100 |
Why?
|
Cisplatin | 6 | 2015 | 1658 | 0.100 |
Why?
|
Adult Stem Cells | 1 | 2014 | 221 | 0.100 |
Why?
|
Spouses | 1 | 2015 | 288 | 0.100 |
Why?
|
Depression | 4 | 2020 | 8237 | 0.100 |
Why?
|
Methotrexate | 8 | 2005 | 1722 | 0.100 |
Why?
|
Carboplatin | 1 | 2015 | 789 | 0.100 |
Why?
|
Alcohol Drinking | 1 | 2025 | 4040 | 0.100 |
Why?
|
Mutation | 8 | 2023 | 30198 | 0.090 |
Why?
|
Pyridines | 2 | 2020 | 2888 | 0.090 |
Why?
|
Tissue Donors | 1 | 2020 | 2395 | 0.090 |
Why?
|
Deglutition Disorders | 1 | 2017 | 639 | 0.090 |
Why?
|
Adolescent | 22 | 2024 | 88835 | 0.090 |
Why?
|
Hodgkin Disease | 7 | 1996 | 1383 | 0.090 |
Why?
|
Socioeconomic Factors | 6 | 2021 | 7838 | 0.090 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2014 | 647 | 0.090 |
Why?
|
Granulocyte Colony-Stimulating Factor | 3 | 2010 | 633 | 0.090 |
Why?
|
Radiation Injuries | 2 | 2017 | 1181 | 0.080 |
Why?
|
Disease-Free Survival | 8 | 2019 | 6832 | 0.080 |
Why?
|
Prognosis | 17 | 2021 | 29922 | 0.080 |
Why?
|
Aged | 40 | 2025 | 171117 | 0.080 |
Why?
|
Deoxycytidine | 1 | 2014 | 889 | 0.080 |
Why?
|
Treatment Outcome | 22 | 2021 | 65188 | 0.080 |
Why?
|
Lymphatic Metastasis | 6 | 2021 | 2887 | 0.080 |
Why?
|
Age Factors | 7 | 2021 | 18380 | 0.080 |
Why?
|
Piperazines | 1 | 2019 | 2549 | 0.080 |
Why?
|
Creatine Kinase | 1 | 1990 | 682 | 0.080 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2011 | 639 | 0.080 |
Why?
|
Live Birth | 2 | 2023 | 516 | 0.080 |
Why?
|
Germ Cells | 2 | 2022 | 647 | 0.080 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 1133 | 0.070 |
Why?
|
Infertility, Female | 1 | 2014 | 763 | 0.070 |
Why?
|
Molecular Targeted Therapy | 2 | 2021 | 2822 | 0.070 |
Why?
|
Pregnancy | 7 | 2024 | 30260 | 0.070 |
Why?
|
Survivors | 3 | 2023 | 2372 | 0.070 |
Why?
|
Interpersonal Relations | 1 | 2015 | 1432 | 0.070 |
Why?
|
Drug Administration Schedule | 4 | 2015 | 4850 | 0.070 |
Why?
|
Medication Adherence | 1 | 2019 | 2192 | 0.070 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2011 | 878 | 0.070 |
Why?
|
Perception | 1 | 2013 | 1205 | 0.070 |
Why?
|
Cohort Studies | 9 | 2024 | 41649 | 0.070 |
Why?
|
Troponin I | 1 | 2011 | 655 | 0.070 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2024 | 4628 | 0.070 |
Why?
|
Pregnancy Outcome | 3 | 2023 | 2966 | 0.060 |
Why?
|
Patient Satisfaction | 2 | 2021 | 3475 | 0.060 |
Why?
|
Multicenter Studies as Topic | 1 | 2011 | 1731 | 0.060 |
Why?
|
Genetic Testing | 2 | 2016 | 3595 | 0.060 |
Why?
|
Risk Factors | 13 | 2024 | 74840 | 0.060 |
Why?
|
Paclitaxel | 5 | 2013 | 1728 | 0.060 |
Why?
|
Diagnosis-Related Groups | 1 | 1987 | 445 | 0.060 |
Why?
|
Biomedical Research | 1 | 2020 | 3458 | 0.060 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2022 | 904 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 2 | 2019 | 5696 | 0.060 |
Why?
|
Filgrastim | 3 | 2010 | 131 | 0.060 |
Why?
|
Sexual Behavior | 1 | 2014 | 2193 | 0.060 |
Why?
|
Wine | 1 | 2025 | 172 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7425 | 0.060 |
Why?
|
Time Factors | 9 | 2020 | 40065 | 0.060 |
Why?
|
Taxoids | 1 | 2007 | 665 | 0.050 |
Why?
|
North America | 2 | 2024 | 1285 | 0.050 |
Why?
|
Medical Oncology | 1 | 2015 | 2339 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 3 | 2022 | 18071 | 0.050 |
Why?
|
Diarrhea | 1 | 2010 | 1316 | 0.050 |
Why?
|
Reticulocytes | 2 | 1974 | 287 | 0.050 |
Why?
|
Heterozygote | 2 | 2022 | 2794 | 0.050 |
Why?
|
Aged, 80 and over | 10 | 2020 | 59489 | 0.050 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2025 | 558 | 0.050 |
Why?
|
Hospitals, Teaching | 1 | 1987 | 1158 | 0.050 |
Why?
|
Premenopause | 1 | 2006 | 1037 | 0.050 |
Why?
|
Parity | 2 | 2015 | 931 | 0.050 |
Why?
|
Lymphoma | 3 | 2017 | 1897 | 0.050 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 1990 | 1376 | 0.050 |
Why?
|
Cost of Illness | 2 | 2024 | 1950 | 0.050 |
Why?
|
Ovary | 1 | 2006 | 956 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 3925 | 0.050 |
Why?
|
Cross-Sectional Studies | 5 | 2022 | 26318 | 0.050 |
Why?
|
Axilla | 2 | 2021 | 615 | 0.050 |
Why?
|
Antibodies, Monoclonal | 4 | 2011 | 9249 | 0.050 |
Why?
|
Erythropoietin | 1 | 2005 | 716 | 0.050 |
Why?
|
Genes, BRCA2 | 2 | 2015 | 588 | 0.050 |
Why?
|
Educational Status | 2 | 2019 | 2513 | 0.040 |
Why?
|
Arm | 2 | 2021 | 589 | 0.040 |
Why?
|
Genes, BRCA1 | 2 | 2015 | 750 | 0.040 |
Why?
|
Leukemia, Lymphoid | 1 | 1980 | 307 | 0.040 |
Why?
|
Neutropenia | 1 | 2005 | 893 | 0.040 |
Why?
|
Feasibility Studies | 4 | 2019 | 5302 | 0.040 |
Why?
|
Medication Errors | 1 | 2006 | 786 | 0.040 |
Why?
|
Vinblastine | 3 | 2013 | 483 | 0.040 |
Why?
|
Lung Diseases, Fungal | 1 | 1980 | 123 | 0.040 |
Why?
|
Brain Neoplasms | 2 | 2013 | 9071 | 0.040 |
Why?
|
Fear | 2 | 2021 | 1499 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2019 | 12807 | 0.040 |
Why?
|
Follow-Up Studies | 14 | 2024 | 39193 | 0.040 |
Why?
|
Ketones | 1 | 2020 | 183 | 0.040 |
Why?
|
Furans | 1 | 2020 | 198 | 0.040 |
Why?
|
Pilot Projects | 5 | 2025 | 8733 | 0.040 |
Why?
|
Stroke Volume | 2 | 2011 | 5596 | 0.040 |
Why?
|
C-Reactive Protein | 1 | 2011 | 3850 | 0.040 |
Why?
|
Polyethylene Glycols | 3 | 2010 | 1188 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2013 | 4058 | 0.040 |
Why?
|
Aspergillosis | 1 | 1980 | 242 | 0.040 |
Why?
|
Blood Donors | 1 | 2020 | 342 | 0.040 |
Why?
|
Academies and Institutes | 1 | 2020 | 326 | 0.040 |
Why?
|
Vaginal Diseases | 1 | 2019 | 103 | 0.040 |
Why?
|
Models, Genetic | 1 | 2008 | 3449 | 0.040 |
Why?
|
Drug Hypersensitivity | 1 | 2007 | 902 | 0.040 |
Why?
|
Survival Rate | 10 | 2010 | 12795 | 0.040 |
Why?
|
Ovariectomy | 2 | 2019 | 611 | 0.040 |
Why?
|
Cancer Care Facilities | 1 | 2020 | 426 | 0.040 |
Why?
|
Logistic Models | 3 | 2018 | 13266 | 0.040 |
Why?
|
Mammaplasty | 2 | 2021 | 1264 | 0.040 |
Why?
|
Pregnancy Rate | 1 | 2020 | 655 | 0.040 |
Why?
|
Unemployment | 1 | 2019 | 211 | 0.040 |
Why?
|
Adjuvants, Immunologic | 1 | 2022 | 995 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2011 | 10729 | 0.030 |
Why?
|
Leuprolide | 1 | 2019 | 312 | 0.030 |
Why?
|
Anilides | 1 | 2020 | 415 | 0.030 |
Why?
|
Prevalence | 3 | 2020 | 15842 | 0.030 |
Why?
|
Lactation | 1 | 2019 | 391 | 0.030 |
Why?
|
Heartburn | 1 | 2017 | 71 | 0.030 |
Why?
|
Genomics | 2 | 2023 | 5929 | 0.030 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2021 | 728 | 0.030 |
Why?
|
Heart Diseases | 1 | 2009 | 2821 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2019 | 999 | 0.030 |
Why?
|
Hot Flashes | 1 | 2019 | 330 | 0.030 |
Why?
|
Hormones | 1 | 2020 | 863 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2021 | 1776 | 0.030 |
Why?
|
Anemia | 1 | 2005 | 1511 | 0.030 |
Why?
|
Lymph Node Excision | 2 | 2021 | 1259 | 0.030 |
Why?
|
Incidence | 2 | 2024 | 21480 | 0.030 |
Why?
|
Morbidity | 1 | 2021 | 1749 | 0.030 |
Why?
|
Mediastinum | 1 | 2017 | 271 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2011 | 10383 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12056 | 0.030 |
Why?
|
Infusions, Intra-Arterial | 5 | 1981 | 218 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2020 | 2910 | 0.030 |
Why?
|
Disease Progression | 4 | 2019 | 13632 | 0.030 |
Why?
|
Actuarial Analysis | 5 | 1996 | 366 | 0.030 |
Why?
|
Anemia, Hypochromic | 1 | 1974 | 62 | 0.030 |
Why?
|
Age Distribution | 1 | 2020 | 2858 | 0.030 |
Why?
|
Keratin-14 | 1 | 2014 | 57 | 0.030 |
Why?
|
Keratin-18 | 1 | 2014 | 37 | 0.030 |
Why?
|
Recombinant Proteins | 3 | 2010 | 6493 | 0.030 |
Why?
|
Hepatic Artery | 5 | 1984 | 231 | 0.030 |
Why?
|
Colorado | 1 | 2014 | 167 | 0.030 |
Why?
|
Directive Counseling | 1 | 2015 | 171 | 0.030 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2015 | 6014 | 0.030 |
Why?
|
Models, Psychological | 1 | 2018 | 824 | 0.030 |
Why?
|
Forecasting | 1 | 2003 | 2936 | 0.030 |
Why?
|
Radiotherapy Dosage | 7 | 1999 | 2865 | 0.030 |
Why?
|
Mastectomy, Radical | 1 | 1993 | 19 | 0.030 |
Why?
|
Mastectomy, Simple | 1 | 1993 | 23 | 0.030 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2020 | 1083 | 0.030 |
Why?
|
Spirituality | 1 | 2018 | 430 | 0.030 |
Why?
|
Loss of Heterozygosity | 1 | 2015 | 663 | 0.030 |
Why?
|
Neoplasms | 5 | 1990 | 22340 | 0.030 |
Why?
|
Retrospective Studies | 11 | 2020 | 81514 | 0.030 |
Why?
|
Tissue and Organ Procurement | 1 | 2020 | 989 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2020 | 6203 | 0.020 |
Why?
|
Floxuridine | 3 | 1981 | 44 | 0.020 |
Why?
|
Preoperative Period | 1 | 2014 | 566 | 0.020 |
Why?
|
Weight Gain | 1 | 2022 | 2355 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2007 | 5337 | 0.020 |
Why?
|
Lymph Nodes | 2 | 2019 | 3454 | 0.020 |
Why?
|
Preoperative Care | 2 | 2014 | 2267 | 0.020 |
Why?
|
Child | 6 | 2022 | 80564 | 0.020 |
Why?
|
Proton Pump Inhibitors | 1 | 2017 | 553 | 0.020 |
Why?
|
Body Weight | 1 | 2022 | 4622 | 0.020 |
Why?
|
Digestive System | 2 | 1984 | 244 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2019 | 3602 | 0.020 |
Why?
|
Electrophoresis | 1 | 1990 | 226 | 0.020 |
Why?
|
Recurrence | 4 | 2015 | 8501 | 0.020 |
Why?
|
Genomic Instability | 1 | 2015 | 718 | 0.020 |
Why?
|
Weight Loss | 1 | 2022 | 2710 | 0.020 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 1980 | 1434 | 0.020 |
Why?
|
Bone Marrow Transplantation | 2 | 1990 | 2729 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2014 | 1837 | 0.020 |
Why?
|
Biomarkers, Pharmacological | 1 | 2011 | 162 | 0.020 |
Why?
|
Delayed Diagnosis | 1 | 2013 | 452 | 0.020 |
Why?
|
Cardiac Electrophysiology | 1 | 2009 | 60 | 0.020 |
Why?
|
Double-Blind Method | 4 | 2005 | 12437 | 0.020 |
Why?
|
Esthetics | 1 | 1991 | 326 | 0.020 |
Why?
|
Mice, SCID | 1 | 2014 | 2630 | 0.020 |
Why?
|
Alkylating Agents | 2 | 1986 | 134 | 0.020 |
Why?
|
Tumor Burden | 1 | 2015 | 1885 | 0.020 |
Why?
|
Heart Failure | 1 | 2013 | 11840 | 0.020 |
Why?
|
Social Class | 1 | 2018 | 2007 | 0.020 |
Why?
|
Population Surveillance | 1 | 2019 | 2590 | 0.020 |
Why?
|
Carmustine | 3 | 1990 | 137 | 0.020 |
Why?
|
Odds Ratio | 1 | 2020 | 9649 | 0.020 |
Why?
|
Stress, Physiological | 2 | 1974 | 1402 | 0.020 |
Why?
|
Erythropoiesis | 1 | 1972 | 691 | 0.020 |
Why?
|
Pulmonary Wedge Pressure | 1 | 1989 | 276 | 0.020 |
Why?
|
Alleles | 1 | 2019 | 6897 | 0.020 |
Why?
|
Survival Analysis | 4 | 2005 | 10070 | 0.020 |
Why?
|
Polyglutamic Acid | 1 | 2007 | 46 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2004 | 17075 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2010 | 1701 | 0.020 |
Why?
|
Genes, erbB-2 | 1 | 2007 | 160 | 0.020 |
Why?
|
Heart | 1 | 1999 | 4414 | 0.020 |
Why?
|
Salvage Therapy | 1 | 1993 | 1272 | 0.020 |
Why?
|
Body Mass Index | 2 | 2015 | 13039 | 0.020 |
Why?
|
Vincristine | 5 | 1991 | 1039 | 0.020 |
Why?
|
Administration, Oral | 1 | 2014 | 4015 | 0.020 |
Why?
|
Fees and Charges | 1 | 1987 | 189 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2015 | 2878 | 0.020 |
Why?
|
Gene Amplification | 1 | 2010 | 1091 | 0.020 |
Why?
|
Prednisone | 6 | 1991 | 1565 | 0.020 |
Why?
|
Up-Regulation | 1 | 2014 | 4137 | 0.020 |
Why?
|
Technetium Tc 99m Aggregated Albumin | 1 | 1984 | 68 | 0.010 |
Why?
|
Male | 17 | 2022 | 363698 | 0.010 |
Why?
|
Animals | 4 | 2014 | 168764 | 0.010 |
Why?
|
Genotype | 1 | 2019 | 13024 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2010 | 2505 | 0.010 |
Why?
|
Lung Neoplasms | 3 | 2017 | 13451 | 0.010 |
Why?
|
Pulmonary Valve Stenosis | 1 | 1985 | 164 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14751 | 0.010 |
Why?
|
Liver Neoplasms | 4 | 1981 | 4353 | 0.010 |
Why?
|
Infusions, Parenteral | 2 | 1981 | 395 | 0.010 |
Why?
|
Metabolic Clearance Rate | 1 | 2004 | 360 | 0.010 |
Why?
|
Self Report | 1 | 2015 | 3770 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2023 | 26346 | 0.010 |
Why?
|
Phosphatidylethanolamines | 2 | 1974 | 128 | 0.010 |
Why?
|
Boston | 2 | 2005 | 9338 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2020 | 5508 | 0.010 |
Why?
|
Half-Life | 1 | 2004 | 644 | 0.010 |
Why?
|
Phenotype | 1 | 2020 | 16721 | 0.010 |
Why?
|
Carcinoid Heart Disease | 1 | 1982 | 11 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2014 | 3685 | 0.010 |
Why?
|
Neoplastic Cells, Circulating | 1 | 1989 | 950 | 0.010 |
Why?
|
Malignant Carcinoid Syndrome | 1 | 1982 | 31 | 0.010 |
Why?
|
United States | 2 | 2024 | 72903 | 0.010 |
Why?
|
Mediastinal Neoplasms | 1 | 1985 | 403 | 0.010 |
Why?
|
Gelatin Sponge, Absorbable | 1 | 1981 | 57 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2014 | 3655 | 0.010 |
Why?
|
Emetics | 1 | 1980 | 9 | 0.010 |
Why?
|
Pharmacology, Clinical | 1 | 1981 | 23 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15880 | 0.010 |
Why?
|
Massachusetts | 1 | 2014 | 8875 | 0.010 |
Why?
|
Drug Evaluation | 3 | 1991 | 641 | 0.010 |
Why?
|
Erythrocyte Transfusion | 1 | 2005 | 568 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2014 | 3278 | 0.010 |
Why?
|
Adenocarcinoma | 2 | 1989 | 6364 | 0.010 |
Why?
|
Statistics as Topic | 1 | 1987 | 2352 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2016 | 6547 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 16047 | 0.010 |
Why?
|
Area Under Curve | 1 | 2004 | 1638 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 1 | 2013 | 3230 | 0.010 |
Why?
|
Patient Admission | 1 | 1987 | 1365 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2013 | 3236 | 0.010 |
Why?
|
Procarbazine | 3 | 1985 | 172 | 0.010 |
Why?
|
Mechlorethamine | 3 | 1985 | 129 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2015 | 8611 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2014 | 18973 | 0.010 |
Why?
|
Lymphography | 1 | 1979 | 189 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2014 | 10429 | 0.010 |
Why?
|
Duodenum | 1 | 1981 | 495 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1998 | 5849 | 0.010 |
Why?
|
Drug Therapy, Combination | 4 | 1983 | 6309 | 0.010 |
Why?
|
Surgery, Plastic | 1 | 1985 | 651 | 0.010 |
Why?
|
Conditioning, Classical | 1 | 1980 | 368 | 0.010 |
Why?
|
Physicians | 1 | 2015 | 4588 | 0.010 |
Why?
|
Stomach | 1 | 1981 | 699 | 0.010 |
Why?
|
Adenoma, Islet Cell | 1 | 1977 | 72 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2012 | 4533 | 0.010 |
Why?
|
Ovarian Neoplasms | 2 | 1986 | 4900 | 0.010 |
Why?
|
Laparotomy | 2 | 1995 | 460 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2009 | 3928 | 0.010 |
Why?
|
Blood Transfusion | 2 | 1974 | 1297 | 0.010 |
Why?
|
Respiratory System | 1 | 1979 | 559 | 0.010 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 1998 | 869 | 0.010 |
Why?
|
Ambulatory Care | 1 | 1987 | 2778 | 0.010 |
Why?
|
Radiation Dosage | 1 | 2004 | 1944 | 0.010 |
Why?
|
Edema | 1 | 1999 | 760 | 0.010 |
Why?
|
Osmotic Fragility | 1 | 1974 | 35 | 0.010 |
Why?
|
Phosphorus Radioisotopes | 1 | 1974 | 100 | 0.010 |
Why?
|
Remission Induction | 2 | 1991 | 2411 | 0.010 |
Why?
|
Erythrocytes | 2 | 1974 | 2395 | 0.010 |
Why?
|
Lung | 2 | 1984 | 10033 | 0.010 |
Why?
|
Cell Membrane | 2 | 1974 | 3634 | 0.010 |
Why?
|
Carbon Radioisotopes | 1 | 1974 | 543 | 0.010 |
Why?
|
Abdomen | 1 | 1979 | 1134 | 0.010 |
Why?
|
Isotope Labeling | 1 | 1974 | 389 | 0.010 |
Why?
|
Echocardiography | 2 | 1985 | 5045 | 0.010 |
Why?
|
Splenectomy | 1 | 1974 | 390 | 0.010 |
Why?
|
Lymphocytes | 1 | 1980 | 2599 | 0.010 |
Why?
|
Hemolysis | 1 | 1974 | 406 | 0.010 |
Why?
|
Phosphorus Isotopes | 1 | 1972 | 125 | 0.010 |
Why?
|
Child, Preschool | 4 | 1996 | 42500 | 0.010 |
Why?
|
Chromatography, Thin Layer | 1 | 1972 | 211 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 1991 | 5389 | 0.010 |
Why?
|
Embolization, Therapeutic | 1 | 1981 | 1403 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 1974 | 2548 | 0.010 |
Why?
|
Hemorrhage | 2 | 1974 | 3461 | 0.010 |
Why?
|
Carbon Isotopes | 1 | 1972 | 451 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2007 | 15398 | 0.010 |
Why?
|
Cytoplasm | 1 | 1974 | 1500 | 0.010 |
Why?
|
Bone Marrow | 1 | 1979 | 2921 | 0.010 |
Why?
|
Bone and Bones | 1 | 1979 | 2554 | 0.000 |
Why?
|
Hemoglobins | 1 | 1974 | 1530 | 0.000 |
Why?
|
Glycine | 1 | 1972 | 672 | 0.000 |
Why?
|
Etoposide | 1 | 1990 | 636 | 0.000 |
Why?
|
Cardiac Tamponade | 1 | 1989 | 176 | 0.000 |
Why?
|
Rats | 2 | 1974 | 23707 | 0.000 |
Why?
|
Liver | 2 | 1979 | 7562 | 0.000 |
Why?
|
Receptors, Steroid | 1 | 1987 | 155 | 0.000 |
Why?
|
Skin | 1 | 1979 | 4489 | 0.000 |
Why?
|
Thiotepa | 1 | 1985 | 66 | 0.000 |
Why?
|
Algorithms | 1 | 2005 | 14071 | 0.000 |
Why?
|
Liver Circulation | 1 | 1984 | 163 | 0.000 |
Why?
|
Microcirculation | 1 | 1989 | 1280 | 0.000 |
Why?
|
Radiotherapy, High-Energy | 1 | 1985 | 226 | 0.000 |
Why?
|
Risk | 1 | 1996 | 9591 | 0.000 |
Why?
|
Melphalan | 1 | 1985 | 425 | 0.000 |
Why?
|
Heart Murmurs | 1 | 1982 | 92 | 0.000 |
Why?
|
Bleomycin | 1 | 1983 | 491 | 0.000 |
Why?
|
Hysterectomy | 1 | 1986 | 864 | 0.000 |
Why?
|
Pulmonary Valve Insufficiency | 1 | 1982 | 140 | 0.000 |
Why?
|
Dacarbazine | 1 | 1983 | 552 | 0.000 |
Why?
|
Colloids | 1 | 1980 | 122 | 0.000 |
Why?
|
Perfusion | 1 | 1984 | 1407 | 0.000 |
Why?
|
Technetium | 1 | 1980 | 326 | 0.000 |
Why?
|
Sulfur | 1 | 1980 | 158 | 0.000 |
Why?
|
Nitrosourea Compounds | 1 | 1978 | 32 | 0.000 |
Why?
|
Physical Examination | 1 | 1985 | 1266 | 0.000 |
Why?
|
Hepatic Veins | 1 | 1978 | 112 | 0.000 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 1982 | 363 | 0.000 |
Why?
|
Tolbutamide | 1 | 1977 | 23 | 0.000 |
Why?
|
Diazoxide | 1 | 1977 | 52 | 0.000 |
Why?
|
Streptozocin | 1 | 1977 | 189 | 0.000 |
Why?
|
Serum Albumin | 1 | 1980 | 675 | 0.000 |
Why?
|
Reoperation | 1 | 1986 | 4294 | 0.000 |
Why?
|
Tissue Distribution | 1 | 1980 | 2266 | 0.000 |
Why?
|
Radionuclide Imaging | 1 | 1980 | 1978 | 0.000 |
Why?
|
Leucine | 1 | 1977 | 546 | 0.000 |
Why?
|
Glucagon | 1 | 1977 | 533 | 0.000 |
Why?
|
Veins | 1 | 1978 | 764 | 0.000 |
Why?
|
Mammography | 1 | 1985 | 2423 | 0.000 |
Why?
|
Gastrointestinal Diseases | 1 | 1981 | 1203 | 0.000 |
Why?
|
Infant | 1 | 1995 | 36386 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 1995 | 15652 | 0.000 |
Why?
|
Insulin | 1 | 1977 | 6599 | 0.000 |
Why?
|
Blood Glucose | 1 | 1977 | 6424 | 0.000 |
Why?
|